Reading BCAB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BCAB free→Reading BCAB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BCAB free→QuarterlyIQ Insights · BCAB
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On March 31, 2026, BioAtla, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Mr. Vasquez and Dr. Sievers Retention Bonuses In lieu of a bonus plan for the first eight months of 2026, on March 17, 2026, the Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of BioAtla, Inc. (the “Company”) approved a retention bonus program for certain Company employees, including the following exec…
A copy of the press release announcing the formal process is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Amendment No. 1 to Agreement and Plan of Merger As previously disclosed, on January 30, 2026, the Company entered into the Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which (i) a wholly owned subsidiary (the “Merger Sub”) will merge with and into the Company, with the Company surviving (the “Merger”), (ii) every fifty (50) shares of Commo…
Regulation FD. As previously disclosed, on February 8, 2026, The Nasdaq Stock Market LLC (“Nasdaq”) Office of General Counsel notified the Company that the Nasdaq Listing and Hearing Review Council (the “Listing Council”) has called for review Nasdaq’s February 6, 2026, decision (the “Delist Determination”) to suspend trading in the Company’s securities effective upon the open of the market on February 10, 2026, and ultimately delist the Company’s securities from, Nasdaq. Nasdaq had determine…
Other Events. Formal Process to Explore and Evaluate Strategic Options On March 2, 2026, the Company announced that it has initiated a formal process to explore and evaluate strategic options to maximize shareholder value, including sale of preclinical and clinical assets, licensing transactions, strategic partnerships or other corporate transactions. In connection with the evaluation of strategic alternatives, the Company is implementing a restructuring plan that includes a workforce reducti…
and Item 7.01, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act, except as shall be expressly set forth by specific reference in such filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Richard Waldron’s employment and role as Chief Financial Officer of the Company will terminate effective as of March 2, 2026. The Company has offered Mr. Waldon severance pursuant to a mutual separation agreement providing for (i) a prorated portion of his salary and benefits through March 31, 2026, (ii) extension of the exercise period of his vest…
Other Events. On February 8, 2026, The Nasdaq Stock Market LLC (“Nasdaq”) Office of General Counsel notified BioAtla, Inc. (the “Company”) that the Nasdaq Listing and Hearing Review Council (the “Listing Council”) has called for review Nasdaq’s February 6, 2026, decision (the “Delist Determination”) to suspend trading in the Company’s securities effective upon the open of the market on February 10, 2026, and ultimately delist the Company’s securities from, Nasdaq. In rendering its decision, t…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 6, 2026, BioAtla, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to suspend the Company’s securities from Nasdaq (the “Delist Determination”) based upon (i) the Company’s non-compliance with the $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) and (ii) the Comp…
Regulation FD. As previously disclosed, on November 20, 2025, the Company entered into Pre-Paid Advance Agreements (the “PPAs”) with each of YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”), Anson Investments Master Fund LP and Anson East Master Fund LP (collectively, the “Investors”). Pursuant to the PPAs, the Investors agreed to advance to the Company $7.5 million. Also on November 20, 2025 (the “Effective Date”), the Company entered into the Standby Equity Purchase…
Regulation FD. As previously disclosed, on December 30, 2025, BioAtla entered into an Investment Agreement (the “Investment Agreement”) with Inversagen AI, LLC, a Delaware limited liability company (“Inversagen AI”), and Alliance International Resources Corp., a Nevada corporation (“AIRC”). Subject to completion of financings by Inversagen AI as set forth in the Investment Agreement, with the initial investment into Inversagen AI being led by AIRC, BioAtla agreed to sell common units of a who…
Other Events As previously reported, on August 6, 2025, the Company was formally notified by the Nasdaq Listing Qualifications Staff (the “Staff”) that the Company no longer satisfied the $1.00 bid price requirement and the $10 million stockholders’ equity requirement (or the alternative standards of $50 million in market value of listed securities (“MVLS”) or $50 million in total assets and $50 million in total revenue) for continued listing on The Nasdaq Global Market under Nasdaq Listing R…
Unregistered Sales of Equity Securities. On January 9, 2026, the Board of Directors (the “Board”) of BioAtla, Inc. (the “Company”) authorized the issuance of one (1) share of Series A Junior Preferred Stock, par value $0.0001 per share (the “Super-Voting Share”), to Jay M. Short, Ph.D., the Company’s Chairman, Chief Executive Officer and co-founder, for the purchase price of $0.01. The Series A Preferred Stock was offered and sold by the Company pursuant to an exemption from the registration…
Other Events. As previously disclosed, on December 30, 2025, the Company originally convened its special meeting of stockholders (the “Special Meeting”). The Special Meeting was held to consider the following proposals: (1) the potential issuance of 20% or more of the aggregate number of the Common Stock issued and outstanding as of November 20, 2025 pursuant to the Pre-Paid Advance Agreements, dated November 20, 2025, by and between the Company and each of YA II PN, Ltd., a Cayman Islands ex…
Entry into a Material Definitive Agreement. On December 30, 2025, BioAtla, Inc. (“the Company” or “BioAtla”) entered into an Investment Agreement (the “Investment Agreement”) with Inversagen AI, LLC, a Delaware limited liability company (“Inversagen AI”), and Alliance International Resources Corp., a Nevada corporation (“AIRC”). Subject to completion of financings by Inversagen AI as set forth in the Investment Agreement, with the initial investment led by AIRC to close by January 30, 2025, t…
Pursuant to the Investment Agreement, the SPV common units will be sold to Inversagen AI in a private placement exempt from the registration requirements of the Securities Act in reliance on Section 4(a)(2) of the Securities Act. The SPV common units have not been registered under the Securities Act and none of such common units may be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. N…
Regulation FD. In connection with the entry into the Investment Agreement, the Company issued a press release, a copy of which is furnished as Exhibit 99.1 to this Current Report. The information included in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statem…
Entry into a Material Definitive Agreement. Pre-Paid Advance Agreement On November 20, 2025, BioAtla, Inc. (the “Company”) entered into Pre-Paid Advance Agreements (the “PPAs”) with each of YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”), Anson Investments Master Fund LP and Anson East Master Fund LP (collectively, the “Investors”). Pursuant to the PPAs, the Investors agreed to advance to the Company $7.5 million (the “Pre-Paid Advance”). The Pre-Paid Advance will be…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure regarding the Pre-Paid Advance set forth in
Results of Operations and Financial Condition. On November 13, 2025, BioAtla, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025 and provided an update on its ongoing clinical programs. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information set forth in
of this Current Report on Form 8-K (this “Current Report”) contains forward-looking statements. All statements other than statements of historical facts contained herein, including, but not limited to, statements regarding the Company’s ability to regain compliance with the Minimum Stockholder’s Equity Requirement and the Minimum Bid Price Requirement, ability to execute on its Compliance Plan successfully, the ability to complete transactions, including strategic partnerships, and its expect…
Results of Operations and Financial Condition. On August 7, 2025, BioAtla, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025 and provided an update on its ongoing clinical programs. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) 2025 Corporate Bonus Plan On June 17, 2025, the Compensation Committee of the Board of Directors of BioAtla, Inc. (the “ Company ”) approved the Company’s 2025 Corporate Bonus Plan (the “Bonus Plan”) subject to corporate performance goals for 2025. The Company’s Chief Executive Officer, Chief Financial Officer, and each of the Company’s named e…
of this Current Report contains forward-looking statements. All statements other than statements of historical facts contained herein, including, but not limited to, statements regarding the Company’s ability to regain compliance with the Minimum Stockholder Equity Requirement and the Company’s intentions to submit a Compliance Plan to Nasdaq within the required time period are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe h…
Results of Operations and Financial Condition. On May 6, 2025, BioAtla, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025 and provided an update on its ongoing clinical programs. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information set forth in
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.